WO2022098083A1 - Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 - Google Patents
Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2022098083A1 WO2022098083A1 PCT/KR2021/015794 KR2021015794W WO2022098083A1 WO 2022098083 A1 WO2022098083 A1 WO 2022098083A1 KR 2021015794 W KR2021015794 W KR 2021015794W WO 2022098083 A1 WO2022098083 A1 WO 2022098083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flt3
- pharmaceutical composition
- methyl
- leukemia
- compound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 42
- 208000032839 leukemia Diseases 0.000 title claims abstract description 22
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 62
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims abstract description 62
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 230000035772 mutation Effects 0.000 claims description 45
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 20
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims description 8
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 description 33
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 108091000080 Phosphotransferase Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102000020233 phosphotransferase Human genes 0.000 description 19
- 201000010099 disease Diseases 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 102000001253 Protein Kinase Human genes 0.000 description 12
- 108060006633 protein kinase Proteins 0.000 description 12
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108010016672 Syk Kinase Proteins 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- -1 cyano, nitro, amino Chemical group 0.000 description 5
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229950006304 gilteritinib Drugs 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- FZLSDZZNPXXBBB-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1 FZLSDZZNPXXBBB-KDURUIRLSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 238000003749 KINOMEscan Methods 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- NSAVYJHNZUQTFP-UHFFFAOYSA-N 1-cyano-1-nitrourea Chemical compound NC(=O)N(C#N)[N+]([O-])=O NSAVYJHNZUQTFP-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MNPVYGOUSLAGOL-HDICACEKSA-N 2-[[5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-4-cyclopropyl-6-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenol Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C(=CC(=C1)C1CC1)CN1C[C@H](N[C@H](C1)C)C)O)C1=CNC2=CC(=CC=C12)C MNPVYGOUSLAGOL-HDICACEKSA-N 0.000 description 1
- OZTDPXUKBRMWSP-HDICACEKSA-N 4-[[5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino]-2-cyclopropyl-6-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenol Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C(=C1)CN1C[C@H](N[C@H](C1)C)C)O)C1CC1)C1=CNC2=CC(=CC=C12)C OZTDPXUKBRMWSP-HDICACEKSA-N 0.000 description 1
- FZLSDZZNPXXBBB-RTBURBONSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5R)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@H](N[C@@H](C1)C)C)C1CC1)C1=CNC2=CC(=CC=C12)C FZLSDZZNPXXBBB-RTBURBONSA-N 0.000 description 1
- ZJSORSYTMDVMJN-BGYRXZFFSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@H](N([C@H](C1)C)C)C)C1CC1)C1=CNC2=CC(=CC=C12)C ZJSORSYTMDVMJN-BGYRXZFFSA-N 0.000 description 1
- LFWWJPOPJQWBOW-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(5-methoxy-6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@H](N[C@H](C1)C)C)C1CC1)C1=CNC2=CC(=C(C=C12)OC)C LFWWJPOPJQWBOW-KDURUIRLSA-N 0.000 description 1
- HYRLQYXURGVEED-CALCHBBNSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@H](N[C@H](C1)C)C)C1CC1)C1=CNC2=CC(=CC=C12)F HYRLQYXURGVEED-CALCHBBNSA-N 0.000 description 1
- QONDOXOMXLPUDZ-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-methoxy-6-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1C1=CNC2=CC(=CC=C12)C)NC1=CC(=CC(=C1)CN1C[C@H](N[C@H](C1)C)C)C1CC1)OC QONDOXOMXLPUDZ-KDURUIRLSA-N 0.000 description 1
- XJQRUFSGSWQQJA-XXBNENTESA-N 5-chloro-N-[3-cyclopropyl-5-[[(3S,5R)-3-ethyl-5-methylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@@H](N[C@@H](C1)C)CC)C1CC1)C1=CNC2=CC(=CC=C12)C XJQRUFSGSWQQJA-XXBNENTESA-N 0.000 description 1
- FZLSDZZNPXXBBB-OALUTQOASA-N 5-chloro-N-[3-cyclopropyl-5-[[(3S,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1C[C@@H](N[C@H](C1)C)C)C1CC1)C1=CNC2=CC(=CC=C12)C FZLSDZZNPXXBBB-OALUTQOASA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FZLSDZZNPXXBBB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1CC(NC(C1)C)C)C1CC1)C1=CNC2=CC(=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=CC(=C1)CN1CC(NC(C1)C)C)C1CC1)C1=CNC2=CC(=CC=C12)C FZLSDZZNPXXBBB-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- NNUKURJVFIGTHC-BGYRXZFFSA-N N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(1H-indol-3-yl)-5-methylpyrimidin-2-amine Chemical compound C1(CC1)C=1C=C(C=C(C=1)CN1C[C@H](N[C@H](C1)C)C)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)C NNUKURJVFIGTHC-BGYRXZFFSA-N 0.000 description 1
- SYDXJXBSEUXLPZ-OYRHEFFESA-N N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-5-methyl-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound C1(CC1)C=1C=C(C=C(C=1)CN1C[C@H](N[C@H](C1)C)C)NC1=NC=C(C(=N1)C1=CNC2=CC(=CC=C12)C)C SYDXJXBSEUXLPZ-OYRHEFFESA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a pharmaceutical composition for the treatment of leukemia comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
- FLT3 Fms-like tyrosine kinase-3
- Kinases mediate the transfer of phosphate groups of high-energy molecules, particularly ATP, to substrates. Kinases are responsible for stabilizing phosphate anhydride bonds and increasing the reaction rate by locating substrates and phosphate groups at specific positions. In most cases, the transition state resulting from interaction with a negatively charged phosphate group is electrostatically stabilized through positively charged surrounding amino acids, and some kinases use metal cofactors to coordinate with a phosphate group.
- Kinases can be divided into various groups, such as protein kinases, lipid kinases, and carbohydrate kinases, according to their substrates and properties. Proteins, lipids, or carbohydrates may change their activity, reactivity, and ability to bind other molecules depending on their phosphorylation state. Kinases have a wide range of effects on intracellular signal transduction and regulate complex biological mechanisms inside cells. The activity of some molecules may be enhanced or inhibited through phosphorylation, and their ability to interact with other molecules may be modulated. Because many kinases respond to environmental conditions or signals, cells can control molecules within the cell depending on context through kinases. Therefore, kinases play a very important role in cell growth, differentiation, proliferation, survival, metabolism, signal transduction, cell transport, secretion, and numerous other cellular response pathways.
- kinases are found in a variety of species from bacteria to fungi, insects and mammals, and more than 500 kinases have been discovered in humans to date.
- Protein kinases can increase or decrease the activity of proteins, stabilize them or mark them for degradation, localize them in specific cellular compartments, and initiate or disrupt interactions with other proteins. Protein kinases are known to account for most of the total kinases, and have been an important research subject. Protein kinases, together with phosphatase, play a role in regulating proteins and enzymes as well as in cell signaling. Cellular proteins are subjected to numerous covalent bonds, but there are not many reversible covalent bonds like phosphorylation, so protein phosphorylation plays a regulatory role. It can be described as having Protein kinases often have multiple substrates, and sometimes a specific protein may act as a substrate for more than one kinase.
- protein kinases are named using factors that regulate their own activity. For example, calmodulin-dependent protein kinases are regulated by calmodulin. Sometimes kinases are divided into subgroups. For example, type 1 and type 2 cyclic AMP-dependent protein kinases are composed of the same enzymatic subunit, but different regulatory subunits are regulated by binding to cyclic AMP.
- Protein kinases are enzymes that catalyze the phosphorylation of hydroxyl groups located at tyrosine, serine, and threonine residues of proteins, and play an important role in growth factor signaling leading to cell growth, differentiation and proliferation (Melnikova, I. et al . al ., Nature Reviews Drug Discovery, 3 (2004), 993), it has been reported that abnormal expression or mutation of specific kinases in cancer cells is frequent.
- RTK Receptor tyrosine kinase
- the extracellular part of the receptor is a part to which a specific ligand binds, and the intracellular part performs the function of transmitting the activation signal of the receptor activated by the ligand into the cell.
- Receptor tyrosine kinase has a domain having tyrosine kinase activity at the C-terminal portion exposed in the cell, and when a specific ligand is attached to the extra-longitudinal portion, it is a kinase enzyme of the C-terminal tyrosine kinase domain exposed to the cytoplasmic portion of the receptor protein. is activated, and phosphorylates tyrosine at the C-terminus of each other on the duplex. The phosphorylation process of tyrosine is the most important process in which a signal for extracellular stimuli is transmitted into the cell. Receptors having tyrosine kinase activity to deliver extracellular stimuli into cells with such a mechanism are well known. Representative examples include FLT3, VEGFR, SYK, and the like.
- the receptor tyrosine kinase FMS-like tyrosine kinase FMS-like tyrosine kinase (Fms-like tyrosine kinase 3: FLT3) is normally expressed in hematopoietic progenitor cells by hematopoietic cells, and plays an important role in the expression of normal stem cells and the immune system. .
- FLT3 the receptor tyrosine kinase FMS-like tyrosine kinase FMS-like tyrosine kinase
- FLT3 the receptor tyrosine kinase FMS-like tyrosine kinase
- AML Acute myeloid leukemia
- FLT3 has recently been considered as one of the most important targets from the therapeutic point of view of AML.
- FLT3 gene mutations are found in approximately 30% of adult AML.
- the most representative problem in AML is that mutations in FLT3 that cause a poor prognosis are activated.
- FLT3 mutations are largely classified into two types. One is internal tandem duplications (ITD) in the juxtamembrane region, and the other is a point mutation in the tyrosine kinase domain (TKD).
- ITD internal tandem duplications
- TKD tyrosine kinase domain
- FLT3-ITD the most frequently detected mutation, is activated in about 23% of patients with early AML. Patients with ITD mutations have a poor prognosis and a high recurrence rate.
- FLT3 TKD FLT3 TKD mutation
- the point mutation in the residue of aspartate 835 (D835), which is replaced by various amino acids, is one of the most common mutations, although less common than the ITD mutation.
- another major activation method of FLT3 in AML is overexpression of wild type FLT3 protein.
- FLT3-ITD is a driver lesion that plays a causative role in malignancy, and can be an effective therapeutic target in human AML (Non-Patent Document 1).
- Mutation of the FLT3 gene is a frequent phenomenon in AML, and usually involves point mutation of the juxtamembrane domain coding region (ITD) or tyrosine kinase domain (TKD).
- FLT3-ITD mutations and FLT3-TKD mutations cause ligand-independent proliferation due to component dimerization and activation of the FLT3 receptor.
- a high mutation rate compared to the wild-type allele of FLT3-ITD is associated with a very poor prognosis in both adults and children (Non-Patent Document 2).
- Other types of leukemia such as chronic myelomonocytic leukemia (CMML), may also carry activating mutations in FLT3. Therefore, FLT3 having an activating mutation is an important target for several cancer types (Non-Patent Document 3 and Non-Patent Document 4).
- TKD mutations have been reported as various acquired resistances in the analysis of patients with refractory/relapsed acute myeloid leukemia to already approved drugs or FLT3 inhibitors under development.
- Representative examples include K429A mutation in receptor domain (RD), Y572C in JM domain, A627P, N676K/D/I/S, F691L in TK1 domain, and D835Y/F/I/H/V/A, Y842C/ in TK2 domain. H/N, etc.
- F691L is the most important acquired resistance in the analysis of resistance patients in FLT3 inhibitor clinical trials, and in the case of F691L, it is a gatekeeper mutation that can inhibit drug activity. Therefore, the development of a drug that can target F691L alone or a double mutation of ITD-F691L is considered unmet medical care (Non-Patent Document 6).
- Spleen tyrosine kinase which is mainly expressed in blood cells, plays an important role in signaling pathways of B-cell receptors and other immune receptors such as mast cells. Splenic tyrosine kinase is also expressed in non-hematopoietic cells such as neurons and vascular endothelial cells. Recent studies have demonstrated that IL-1, TNF- ⁇ , and ITGB1 play an important role in the oxidation of various cellular stimuli including ITGB1. SYK is known as a potentially good target in various hematologic malignancies, autoimmune diseases, and other inflammatory reactions (Non-Patent Document 7 and Non-Patent Document 8).
- Non-Patent Document 1 Catherine et al ., Nature, 2012, 485, 260-263
- Non-Patent Document 2 AS Moore et al ., Leukemia, 2012, 26, 1462-1470
- Non-Patent Document 3 Cancer Cell, (2007), 12: 367-380
- Non-Patent Document 4 Current Pharmaceutical Design (2005), 11, 3449-3457
- Non-Patent Document 5 H Kiyoi et al ., Cancer Science (2020), 111, 312
- Non-Patent Document 6 Christine et al ., Cancer Discovery , 9, (2019), 1050
- Non-Patent Document 7 Liu et al ., Journal of Hematology & Oncology (2017), 10, 145
- Non-Patent Document 8 Yamada T et al ., J. Immunol., (2001) 167, 283-288
- One aspect of the present invention is to provide a pharmaceutical composition for the treatment of leukemia comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
- FLT3 Fms-like tyrosine kinase-3
- Another aspect of the present invention is to provide a pharmaceutical use for the treatment of cancer having an F691L acquisition mutation according to the aspect.
- One aspect of the present invention provides a pharmaceutical composition for the treatment of leukemia comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
- FLT3 Fms-like tyrosine kinase-3
- Another aspect of the present invention provides a pharmaceutical use for the treatment of cancer having an F691L acquisition mutation according to the above aspect.
- One embodiment is a pharmaceutical composition
- a pharmaceutical composition comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient,
- the FLT3 inhibitor is at least one compound selected from the group consisting of a compound of Formula 1 below, a stereoisomer thereof, a tautomer thereof, and a combination thereof;
- the pharmaceutical composition is a pharmaceutical composition for the treatment of leukemia, wherein the leukemia cancer cells have an internal tandem duplication (ITD) mutation in the FLT3 gene,
- composition further comprising at least one FLT3 mutation selected from F691L, D835Y, D835F, D835I, D835H, D835V and D835A.
- the leukemia is acute myeloid leukemia (AML).
- AML acute myeloid leukemia
- the pharmaceutical composition may be administered concurrently or sequentially with the SYK inhibitor.
- the term “simultaneous” administration refers to the administration of two or more components simultaneously or substantially simultaneously by the same route, and when administered substantially simultaneously, the route of administration may be the same or different.
- the term “sequential” administration refers to administration of two or more components at different times, and the administration route may be the same or different.
- Another embodiment of the pharmaceutical composition comprising the FLT3 inhibitor is as follows.
- R 1 is hydrogen, halogen, hydroxy, C 1-4 alkoxy or —NR a R b ego,
- R a and R b are each independently hydrogen or C 1-4 alkyl
- R 2 is hydrogen, halogen, cyano, nitro, amino, carboxamide, formyl, haloC 1-4 alkyl or C 1-4 alkyl;
- R 3 is hydrogen, halogen, hydroxy, haloC 1-4 alkyl, C 1-4 alkyl, C 2-4 alkenyl or C 2-4 alkynyl;
- R c is C 1-4 alkyl or —NR d R e ,
- R d and R e is each independently hydrogen or C 1-4 alkyl
- l is an integer from 0 to 2;
- k is an integer from 0 to 4.
- R 5 and each R 6 is independently hydrogen, halogen, hydroxy, nitro, amino, C 1-4 alkoxy or C 1-4 alkyl;
- R 7 is hydroxyC 1-4 alkyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl or C 3-9 heterocycloalkyl;
- C 3-7 cycloalkyl or C 3-9 heterocycloalkyl may be unsubstituted or substituted with halogen, C 1-4 alkyl or haloC 1-4 alkyl;
- X is H or OH
- the compound of formula (A) may comprise a tautomeric structure such as the following formula (B),
- R 3 , R 4 , and k are as defined in formula (A);
- Y is -(CH 2 ) m -, -(CH 2 ) m -O-(CH 2 ) n -, -(CH 2 ) m -CO-(CH 2 ) n -, -(CH 2 ) m -NR 8 -(CH 2 ) n - or -(CH 2 ) m -SO 2 -(CH 2 ) n -;
- R 8 is hydrogen or C 1-4 alkyl
- n are each independently an integer from 0 to 2;
- Z is a structure of formula (C);
- R 9 is halogen, hydroxy, cyano, nitro, amino, thiol, formyl, haloC 1-4 alkyl, C 1-4 alkoxy, straight-chain or branched hydroxyC 1-4 alkyl, straight-chain or branched C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-10 cycloalkyl, C 2-9 heterocycloalkyl, hydroxyC 2-9 heterocycloalkyl, straight chain or branched hydroxyC 1-4 alkylcarbonyl, -NR 10 R 11 , -COR 12 , -COOR 12 or -SO 2 R 13 ,
- q is an integer from 0 to 5
- step, q is not 0 when is piperazinyl or piperidine;
- R 9 are connected to each other or can be fused with 7 to 12 membered bicycloalkyl, heterobicycloalkyl, spirocycloalkyl, or spiroheterocycloalkyl;
- R 10 and R 11 are each independently hydrogen, hydroxy C 1-4 Alkyl, HaloC 1-4 alkyl, C 1-4 alkyl, C 2-4 alkenyl or C 2-4 is alkynyl;
- R 12 is hydrogen, hydroxy, hydroxyC 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkyl , C 2-4 alkenyl, C 2-4 alkynyl, C 3-10 cycloalkyl or C 2-9 heterocycloalkyl;
- R 13 is hydroxy, haloC 1-4 alkyl, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-10 cycloalkyl, C 2-9 heterocycloalkyl, aryl or -NR f R g ,
- R f and each R g is independently hydrogen or C 1-4 alkyl.
- a compound of the following formula (D), a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt thereof may be included as an active ingredient.
- E a is hydrogen, hydroxy or C 1-4 alkoxy
- E b is hydrogen, halogen, C 1-4 alkyl or C 1-4 fluoroalkyl
- E c and E d are independently of each other hydrogen or hydroxy
- X' is hydrogen or hydroxy
- k is an integer from 0 to 4.
- each Q is independently of the other hydroxy, halogen, C 1-4 alkyl, hydroxyC 1-4 alkyl or C 1-4 alkoxy;
- Z' is a monovalent functional group shown in formula (E);
- n is an integer of 1 to 8.
- Each substituent A is independently a functional group selected from hydroxy, C 1-4 alkyl and hydroxyC 1-4 alkyl, wherein, when n is 2 or more, two A of n are linked to each other to form an alkyl group
- Z' forms a 7 to 12 membered bridged heterobicycloalkyl ring, or two A's are linked by spiro to form a 7 to 12 membered spiroheterocycloalkyl ring can form;
- L is hydrogen, C 1-4 alkyl, hydroxy or hydroxyC 1-4 alkyl.
- a pharmaceutical composition comprising the compound in (2) above, wherein E b is halogen, n is 2, and A is methyl.
- a pharmaceutical composition comprising a compound in (2) above, wherein E b is chlorine or fluoro.
- the compound of formula A is a pharmaceutical composition comprising a compound selected from the group consisting of:
- the pharmaceutical composition further comprising a pharmaceutically acceptable additive.
- the pharmaceutical composition according to (8), wherein the leukemia is acute myeloid leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia.
- a pharmaceutical composition for the treatment of cancer having a mutation in the tyrosine kinase domain (TKD) (FLT3-TKD) of the FLT3 amino acid sequence In (1) or (2) above, a pharmaceutical composition for the treatment of cancer having a mutation in the tyrosine kinase domain (TKD) (FLT3-TKD) of the FLT3 amino acid sequence.
- TKD tyrosine kinase domain
- composition according to (14), wherein the cancer is acute myeloid leukemia (AML) having F691L alone or ITD-F691L double mutation.
- AML acute myeloid leukemia
- FLT3 herein is a member of the class III receptor tyrosine kinase (TK) family that is commonly expressed on the surface of hematopoietic stem cells. FLT3 and its ligands play important roles in proliferation, survival and differentiation of pluripotent stem cells. FLT3 is expressed in many AML cases.
- activated FLT3 with intragenic tandem duplication (ITD) in and around the proximal domain and tyrosine kinase domain (TKD) mutations near D835 in the activation loop are 28% to 34% and 11% to 11% of AML cases, respectively. present at 14%. These activating mutations in FLT3 are tumorigenic and exhibit transforming activity in cells.
- cancer is a leukemia such as acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia, CLL), acute promyelocytic leukemia (APL), hairy cell leukemia, chronic neutrophilic leukemia (CNL), and the like.
- AML acute myelogenous leukemia
- CML chronic myelogenous leukemia
- ALL acute lymphocytic leukemia
- CLL chronic lymphocytic leukemia
- APL acute promyelocytic leukemia
- hairy cell leukemia chronic neutrophilic leukemia
- CCL chronic neutrophilic leukemia
- the cancer may be leukemia.
- the leukemia may include acute myeloid leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia.
- Acute myeloid leukemia herein includes acute myeloid leukemia with a FLT3 mutation.
- the acute myeloid leukemia comprises a mutant FLT3 polynucleotide-positive myeloid leukemia, a longitudinal duplication (ITD) positive acute myeloid leukemia in the FLT3 gene, or an acute myeloid leukemia having a FLT3 point mutation.
- the FLT3 point mutation may be a mutation in a tyrosine kinase domain (TKD) (FLT3-TKD) region of the FLT3 amino acid sequence.
- TKD tyrosine kinase domain
- “Pharmaceutically acceptable” as used herein generally refers to a composition or component of a composition that is non-toxic, inert, and/or physiologically compatible.
- “Pharmaceutical excipient” or “excipient” includes substances such as adjuvants, carriers, pH-adjusting and buffering agents, isotonicity adjusting agents, wetting agents, preservatives, and the like.
- “Pharmaceutical excipient” is a pharmaceutically acceptable excipient.
- the pharmaceutical composition may include conventional pharmaceutically acceptable excipients or additives.
- the pharmaceutical composition of the present invention can be formulated according to a conventional method, and various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, or parenteral administration such as intramuscular, intravenous or subcutaneous administration can be prepared in dosage form.
- examples of carriers, additives, and excipients used include diluents, disintegrants, binders, lubricants, surfactants, suspending agents, or emulsifiers.
- the carrier or additive or excipient includes water, saline, aqueous glucose solution, similar sugar solution, alcohol, glycol, ether (eg, polyethylene glycol 400), oil, fatty acid, and fatty acid esters, glycerides, surfactants, suspending agents, or emulsifiers.
- Such formulation methods are well known to those skilled in the art of pharmaceuticals.
- the compound of Formula A or Formula 1 is an effective amount for treatment or prevention of an individual or patient, and may be administered orally or parenterally as desired, and when administered orally, the active ingredient For parenteral administration, 1 body weight per day based on the active ingredient so as to be administered in an amount of, for example, 0.01 to 1000 mg, 0.01 to 500 mg, 0.1 to 300 mg, or 0.1 to 100 mg per 1 kg of body weight per day as a standard
- the composition may be administered in 1 to several divided doses.
- the dose to be administered to a specific individual or patient should be determined in light of several related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and disease severity, and can be appropriately adjusted or decreased by a specialist. It should be understood that the above dosage is not intended to limit the scope of the present invention in any way.
- Another aspect of the present invention provides a method for preventing or treating cancer using the pharmaceutical composition.
- the dosage, the frequency of administration, or the administration method of the compound used in the treatment method may vary depending on the subject to be treated, the severity of the disease or condition, the rate of administration, and the judgment of the prescribing physician.
- the dosage for a person weighing 70 kg may be administered in an amount of 0.1 to 2,000 mg, for example, 1 to 1,000 mg or 10 to 2,000 mg per day.
- the frequency of administration may be 1 to several times, for example, 1 to 4 times, or an on/off schedule may be administered, and the administration method may be administered through an oral or parenteral route.
- dosages lower than the aforementioned ranges may be more suitable, higher dosages may be used without producing deleterious side effects, and higher dosages may be divided into several smaller dosages throughout the day.
- a physician having ordinary skill in the related art can easily determine and prescribe the dosage of the compound to be used as needed. For example, a physician may start a dose of a compound of the present invention used in a pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.
- the method of treatment may use the compound according to an aspect of the present invention as an active ingredient alone or in combination with one or more other agents or pharmaceutical carriers known for treating cancer, tumor or leukemia.
- the compound of Formula A or Formula 1, a compound selected from stereoisomers, tautomers, solvates, and pharmaceutically acceptable salts thereof is an agent for inhibiting other FLT3 kinase activity or efficacy of inhibiting FLT3 kinase activity
- co-administering it with other drugs with various mechanisms that increase or decrease the level of synergism it is possible to decrease FLT3 activity or enhance the therapeutic effect of FLT3-mediated diseases.
- treatment is used as a concept including all treatment, improvement, amelioration, or management of a disease.
- treating or “treatment” refers to inhibiting a disease, e.g., inhibiting a disease, condition or disorder in an individual experiencing or exhibiting a pathology or symptom of a disease, condition or disorder, pathology. and/or preventing further occurrence of symptoms, ameliorating the disease, or reversing the pathology and/or symptoms, such as reducing disease severity.
- preventing refers to preventing a disease, e.g., a disease in an individual who may be predisposed to the disease, condition or disorder but has not yet experienced or exhibited the pathology or signs of the disease; To prevent a condition or disorder.
- the term “subject” or “patient” refers to any animal, including mammals, eg, mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses or primates and humans. .
- the terms “have”, “may have”, “comprises”, or “may include” indicate the presence of a corresponding characteristic (eg, a numerical value or a component such as a component), The presence of additional features is not excluded.
- the pharmaceutical composition according to an aspect of the present invention has excellent FLT3 inhibitory activity, it can be effectively used for the prevention or treatment of cell proliferative diseases caused by abnormal FLT3 activity, such as cancer, eg, leukemia.
- the pharmaceutical composition may be used for the treatment of cancer, including leukemia having an F691L acquisition mutation.
- FLT3 inhibitor 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H -Indol-3-yl) pyrimidin-2-amine (hereinafter, Compound A) was measured for inhibitory activity against wild-type or mutant FLT3 and SYK.
- LanthaScreen test method wild-type and mutant FLT3 or Z'-LYTE test method (SYK) developed by Thermo Fisher Scientific.
- LanthaScreen assay is based on the binding of Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor (kinase tracer-236) to kinase, europium-conjugated antibody It is a method of measuring the activity of a protein by measuring a fluorescence resonance energy transfer (FRET) signal in the presence.
- FRET fluorescence resonance energy transfer
- the Z'-LYTE test method uses an enzyme capable of cleaving a non-phosphorylated substrate, and is a method to measure the activity of a kinase protein by measuring two fluorescence FRET signals attached to each end of a peptide substrate. Both experiments were performed in a 384 well plate under the conditions of 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , 1 mM EGTA, and 1% DMSO. A background signal is measured in the absence of each kinase, and after measuring by adding only a solvent (1% DMSO) as a non-inhibitory signal, the compound A to be evaluated is added at a set concentration (eg, 50 to 0.05 nM). . The results are shown in Table 1 below.
- the binding ability of compound A to wild-type or mutant FLT3 was measured using DiscoverX's KINOMEscan screening platform.
- the KINOMEscan test method is a method of quantitatively measuring the binding between a substance to be tested and a kinase using a competitive binding assay for the active site of a DNA-linked kinase enzyme using quantitative PCR. am.
- the test was commissioned by DiscoverX, and the binding ability of the inhibitor to each wild-type or mutant FLT3 was calculated as the Kd value. The results are shown in Table 2 below.
- the MOLM-14 FLT3-ITD/F691L cell line was subcutaneously injected into nude mice at 3 ⁇ 10 ⁇ 6 cells/0.15 mL/mouse and allowed to grow.
- the gilteritinib group was orally administered once a day at a dose of 30 mg/kg/day.
- the control group received individual drugs for 13 days, and the drug administration group received individual drugs for 18 days.
- FIG. 1 shows the anti-tumor effect when the control group, Compound A and gilteritinib were administered to nude mice xenografted with MOLM-14 FLT3-ITD/F691L cell line.
- the Y-axis represents the tumor volume (mm 3 ) of surviving mice in each group, and the X-axis represents the dosing days.
- the result of complete response (CR) in which the tumor completely disappeared was confirmed.
- FIG. 1 as a result of measuring and confirming the tumor volume according to drug administration, a complete response of Compound A appeared on the 12th day of administration.
- FIG. 1 shows the anti-tumor effect when the control group, Compound A and gilteritinib were administered to nude mice xenografted with MOLM-14 FLT3-ITD/F691L cell line.
- the Y-axis represents the tumor volume (mm 3 ) of surviving mice in each group
- the X-axis represents the dosing days.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
- Fms-유사 티로신 키나아제(Fms-like tyrosine kinase-3: FLT3) 억제제와 약학적으로 허용되는 부형제를 포함하는 약학적 조성물로서,상기 FLT3 억제제는 하기 화학식 1의 화합물, 이의 입체 이성질체, 이의 호변 이성질체, 및 이들의 조합으로 이루어진 군으로부터 선택하는 적어도 하나의 화합물이거나;이 선택한 적어도 하나의 화합물의 약제학적으로 허용되는 염 또는 이 선택한 적어도 하나의 화합물의 용매화물이며;상기 약학적 조성물은 백혈병의 치료를 위한 약학적 조성물로서, 상기 백혈병 암세포는 FLT3 유전자내 종렬 중복(internal tandem duplication; ITD) 변이를 지니며,F691L, D835Y, D835F, D835I, D835H, D835V와 D835A 중에서 선택하는 적어도 하나의 FLT3 돌연변이를 더 포함하는 약학적 조성물:[화학식 1]
- 제 1항에 있어서, 상기 백혈병은 급성 골수성 백혈병(acute myeloid leukemia: AML)인 것이 특징인 약학적 조성물.
- 제 1항에 있어서, 상기 약학 조성물은 SYK 억제제와 동시에 또는 순차적으로 병용 투여하는 것을 특징으로 하는 약학적 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180084028.6A CN116583284A (zh) | 2020-11-05 | 2021-11-03 | 用于治疗髓性白血病的包括flt3抑制剂的药物组合物 |
EP21889548.0A EP4241773A1 (en) | 2020-11-05 | 2021-11-03 | Pharmaceutical composition for treating leukemia comprising flt3 inhibitor |
CA3197836A CA3197836A1 (en) | 2020-11-05 | 2021-11-03 | Pharmaceutical composition comprising for the treatment of myeloid leukemiea |
JP2023527016A JP2023548190A (ja) | 2020-11-05 | 2021-11-03 | 骨髄性白血病の治療のためのflt3阻害剤を含む医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200147156 | 2020-11-05 | ||
KR10-2020-0147156 | 2020-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022098083A1 true WO2022098083A1 (ko) | 2022-05-12 |
Family
ID=81458079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/015794 WO2022098083A1 (ko) | 2020-11-05 | 2021-11-03 | Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4241773A1 (ko) |
JP (1) | JP2023548190A (ko) |
KR (1) | KR20220061026A (ko) |
CN (1) | CN116583284A (ko) |
CA (1) | CA3197836A1 (ko) |
TW (1) | TW202233193A (ko) |
WO (1) | WO2022098083A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090318446A1 (en) * | 2005-01-11 | 2009-12-24 | Cyclacel Limited | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy |
US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
WO2015154039A2 (en) * | 2014-04-04 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
KR102110573B1 (ko) * | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
KR20200102948A (ko) * | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
-
2021
- 2021-11-03 WO PCT/KR2021/015794 patent/WO2022098083A1/ko active Application Filing
- 2021-11-03 EP EP21889548.0A patent/EP4241773A1/en active Pending
- 2021-11-03 CA CA3197836A patent/CA3197836A1/en active Pending
- 2021-11-03 KR KR1020210149894A patent/KR20220061026A/ko unknown
- 2021-11-03 CN CN202180084028.6A patent/CN116583284A/zh active Pending
- 2021-11-03 JP JP2023527016A patent/JP2023548190A/ja active Pending
- 2021-11-04 TW TW110141175A patent/TW202233193A/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090318446A1 (en) * | 2005-01-11 | 2009-12-24 | Cyclacel Limited | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy |
US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
WO2015154039A2 (en) * | 2014-04-04 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
KR102110573B1 (ko) * | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
KR20200102948A (ko) * | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
Non-Patent Citations (9)
Title |
---|
A S MOORE ET AL., LEUKEMIA, vol. 26, 2012, pages 1462 - 1470 |
CANCER, CELL, vol. 12, 2007, pages 367 - 380 |
CATHERINE ET AL., NATURE, vol. 485, 2012, pages 260 - 263 |
CHRISTINE ET AL., CANCER DISCOVERY, vol. 9, 2019, pages 1050 |
CURRENT PHARMACEUTICAL DESIGN, vol. 11, 2005, pages 3449 - 3457 |
H KIYOI ET AL., CANCER SCIENCE, vol. 111, 2020, pages 312 |
LIU ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, 2017, pages 145 |
MELNIKOVA, I. ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 3, 2004, pages 993 |
YAMADA T ET AL., J. IMMUNOL., vol. 167, 2001, pages 283 - 288 |
Also Published As
Publication number | Publication date |
---|---|
EP4241773A1 (en) | 2023-09-13 |
KR20220061026A (ko) | 2022-05-12 |
CA3197836A1 (en) | 2022-05-12 |
CN116583284A (zh) | 2023-08-11 |
TW202233193A (zh) | 2022-09-01 |
JP2023548190A (ja) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102212923B1 (ko) | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 | |
US7101869B2 (en) | 2,4-diaminopyrimidine compounds useful as immunosuppressants | |
JP2000510870A (ja) | Npy5受容体アンタゴニストとしてのアミド類 | |
ZA200504852B (en) | Novel 2-pyridinecarboxamide derivatives | |
HUE032987T2 (en) | Dihydropyrazolopyrimidinone derivative | |
US7732468B2 (en) | 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof | |
CN111886233B (zh) | 三唑酮衍生物或其盐以及包含其的药物组合物 | |
WO2020171646A1 (ko) | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 | |
WO2020262974A1 (ko) | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
BG106695A (bg) | 2,4-диаминопиримидинови съединения, полезни като антисупресанти | |
CN111386114A (zh) | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 | |
US10300061B2 (en) | Aminothiazole compounds as protein kinase inhibitors | |
WO2020171649A1 (ko) | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 | |
US6245817B1 (en) | NPY5 receptor antagonists and methods for using same | |
WO2020141828A2 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
WO2022098083A1 (ko) | Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 | |
WO2022131741A1 (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
US20170007615A1 (en) | Antibacterial Compounds | |
KR20210076069A (ko) | TGF-βR1 억제제로서의 화합물 및 이의 적용 | |
WO2018030800A1 (ko) | 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1h)-온 골격의 유레아 화합물 | |
WO2021182903A1 (ko) | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 | |
WO2019035522A1 (ko) | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 | |
Alvarez et al. | Inhibition of parasite protein kinase C by new antileishmanial imidazolidin-2-one compounds | |
WO2021066443A1 (ko) | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
WO2021085888A1 (ko) | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21889548 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023527016 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3197836 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021889548 Country of ref document: EP Effective date: 20230605 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084028.6 Country of ref document: CN |